Zimmer Launches Trilogy® Acetabular System Constrained Liner in U.S.
(WARSAW, IN) March 11, 2003 – Zimmer Holdings, Inc. (NYSE:ZMH) announced today that it has begun sales in the United States of the Trilogy® Acetabular System Constrained Liner. Zimmer recently received clearance from the Food and Drug Administration to begin sales of the product, which has been available in markets outside of the U.S. since 2001
"The revision hip market is one of the fastest growing segments in orthopaedics, with procedure growth of nearly 15%, and this addition gives us a comprehensive offering for acetabular revision,” said Ray Elliott, Chairman, President and CEO of Zimmer. "The Trilogy System is already well accepted among surgeons, but the addition of the constrained liner will make the line more attractive to both Zimmer and non-Zimmer customers."
Constrained liners are often used in revision surgeries to address situations where the hip has a tendency to dislocate. The extra constraint provided by the liner design helps keep the hip replacement components properly mated.
“Because the Trilogy Constrained Liner mates with other Trilogy components, surgeons now have the flexibility to leave a well-fixed acetabular shell in place during a revision surgery, and simply insert a new liner,” said Michael J. Anderson, M.D., an orthopaedic surgeon with the Blount Orthopaedic Clinic in Milwaukee. “Revision procedures are typically much more complicated than the initial hip replacement, so it’s important that surgeons have as many tools as possible to address each patient’s revision needs. This will allow us to restore function in many patients who would otherwise be facing ongoing problems with dislocation.”
Zimmer, based in Warsaw, Indiana, is a global leader in the design, development, manufacture and marketing of reconstructive orthopaedic implants and trauma products. Orthopaedic reconstruction implants restore joint function lost due to disease or trauma in joints such as knees, hips, shoulders and elbows. Trauma products are devices used primarily to reattach or stabilize damaged bone and tissue to support the body’s natural healing process. Zimmer also manufactures and markets other products related to orthopaedic and general surgery. For the year 2002, Zimmer recorded worldwide revenues of approximately $1.4 billion. Zimmer was founded in 1927 and has more than 3,600 employees worldwide.
Investor Contact:
Sam Leno
Chief Financial Officer
574/372-4790
sam.leno@zimmer.com
Media Contact:
Brad Bishop
Public Affairs
574/372-4291
bradley.bishop@zimmer.com
